Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis

NCT03191864 is registered in ClinicalTrials.gov with Adare Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03191864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03191864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis
Lead sponsor
Adare Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 22, 2017
Completion date
October 23, 2019
Enrollment
106 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis